Comparative Pharmacology
Head-to-head clinical analysis: NORPACE versus QUINIDINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE versus QUINIDINE SULFATE.
NORPACE vs QUINIDINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction. It also inhibits potassium channels, prolonging repolarization, and has vagolytic and negative inotropic effects.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
300-600 mg orally every 6-8 hours; maximum 2-4 g/day. Extended-release: 300-600 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life is 6-8 hours in healthy adults; prolonged to 12-18 hours in heart failure, hepatic cirrhosis, or severe renal impairment (CrCl < 10 mL/min).
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
Renal excretion of unchanged drug accounts for 10-20% of elimination; hepatic metabolism (hydroxylation and N-oxidation) accounts for 70-80%; about 5% excreted in feces via biliary elimination.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)